Literature DB >> 25786697

Targeting liver X receptors in cancer therapeutics.

Chin-Yo Lin1, Jan-Åke Gustafsson2.   

Abstract

Members of the nuclear receptor superfamily of ligand-dependent transcription factors carry out vital cellular functions and are highly druggable therapeutic targets. Liver X receptors (LXRs) are nuclear receptor family members that function in cholesterol transport, glucose metabolism and the modulation of inflammatory responses. There is now accumulating evidence to support the involvement of LXRs in a variety of malignancies and the potential efficacy of their ligands in these diseases. This Review summarizes the discovery and characterization of LXRs and their ligands, their effects and mechanisms in preclinical cancer models, and the future directions of basic and translational LXR research in cancer therapeutics.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25786697     DOI： 10.1038/nrc3912

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  99 in total

Review 1.  Action mechanisms of Liver X Receptors.

Authors:  Chiara Gabbi; Margaret Warner; Jan-Åke Gustafsson
Journal:  Biochem Biophys Res Commun       Date:  2013-12-01       Impact factor: 3.575

Review 2.  Antiandrogens in prostate cancer endocrine therapy.

Authors:  Z Culig; G Bartsch; A Hobisch
Journal:  Curr Cancer Drug Targets       Date:  2004-08       Impact factor: 3.428

3.  Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor.

Authors:  Elaine M Quinet; Dawn A Savio; Anita R Halpern; Liang Chen; Christopher P Miller; Ponnal Nambi
Journal:  J Lipid Res       Date:  2004-08-01       Impact factor: 5.922

4.  Separate and overlapping metabolic functions of LXRalpha and LXRbeta in C57Bl/6 female mice.

Authors:  Marion Korach-André; Paolo Parini; Lilian Larsson; Anders Arner; Knut R Steffensen; Jan-Ake Gustafsson
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-08-18       Impact factor: 4.310

5.  The oxysterol receptor LXR inhibits proliferation of human breast cancer cells.

Authors:  Lise-Lotte Vedin; Sebastian A Lewandowski; Paolo Parini; Jan-Ake Gustafsson; Knut R Steffensen
Journal:  Carcinogenesis       Date:  2009-01-23       Impact factor: 4.944

6.  Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2.

Authors:  Alessio Noghero; Alessia Perino; Giorgio Seano; Elisa Saglio; Giuseppe Lo Sasso; Franco Veglio; Luca Primo; Emilio Hirsch; Federico Bussolino; Fulvio Morello
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-06-21       Impact factor: 8.311

7.  Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells.

Authors:  A J C Pommier; G Alves; E Viennois; S Bernard; Y Communal; B Sion; G Marceau; C Damon; K Mouzat; F Caira; S Baron; J M A Lobaccaro
Journal:  Oncogene       Date:  2010-03-01       Impact factor: 9.867

8.  LXR activation inhibits chemokine-induced CD4-positive lymphocyte migration.

Authors:  Daniel Walcher; Dusica Vasic; Philipp Heinz; Helga Bach; Renate Durst; Angelina Hausauer; Vinzenz Hombach; Nikolaus Marx
Journal:  Basic Res Cardiol       Date:  2010-04-03       Impact factor: 17.165

9.  Localisation of the oestradiol-binding and putative DNA-binding domains of the human oestrogen receptor.

Authors:  V Kumar; S Green; A Staub; P Chambon
Journal:  EMBO J       Date:  1986-09       Impact factor: 11.598

10.  LXR activation reduces proinflammatory cytokine expression in human CD4-positive lymphocytes.

Authors:  Daniel Walcher; Andreas Kümmel; Bettina Kehrle; Helga Bach; Miriam Grüb; Renate Durst; Vinzenz Hombach; Nikolaus Marx
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-02-16       Impact factor: 8.311
View more
  57 in total

Review 1.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Authors:  Lisa M Butler; Ylenia Perone; Jonas Dehairs; Leslie E Lupien; Vincent de Laat; Ali Talebi; Massimo Loda; William B Kinlaw; Johannes V Swinnen
Journal:  Adv Drug Deliv Rev       Date:  2020-07-23       Impact factor: 15.470

Review 2.  LXRα Phosphorylation in Cardiometabolic Disease: Insight From Mouse Models.

Authors:  Maud Voisin; Matthew C Gage; Natalia Becares; Elina Shrestha; Edward A Fisher; Ines Pineda-Torra; Michael J Garabedian
Journal:  Endocrinology       Date:  2020-07-01       Impact factor: 4.736

3.  Liver X receptor α (LXRα) promoted invasion and EMT of gastric cancer cells by regulation of NF-κB activity.

Authors:  Linhua Ji; Bin Zhang; Gang Zhao
Journal:  Hum Cell       Date:  2017-01-16       Impact factor: 4.174

4.  An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers.

Authors:  Genaro R Villa; Jonathan J Hulce; Ciro Zanca; Junfeng Bi; Shiro Ikegami; Gabrielle L Cahill; Yuchao Gu; Kenneth M Lum; Kenta Masui; Huijun Yang; Xin Rong; Cynthia Hong; Kristen M Turner; Feng Liu; Gary C Hon; David Jenkins; Michael Martini; Aaron M Armando; Oswald Quehenberger; Timothy F Cloughesy; Frank B Furnari; Webster K Cavenee; Peter Tontonoz; Timothy C Gahman; Andrew K Shiau; Benjamin F Cravatt; Paul S Mischel
Journal:  Cancer Cell       Date:  2016-10-13       Impact factor: 31.743

5.  p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression.

Authors:  Sung-Hwan Moon; Chun-Hao Huang; Shauna L Houlihan; Kausik Regunath; William A Freed-Pastor; John P Morris; Darjus F Tschaharganeh; Edward R Kastenhuber; Anthony M Barsotti; Rachel Culp-Hill; Wen Xue; Yu-Jui Ho; Timour Baslan; Xiang Li; Allison Mayle; Elisa de Stanchina; Lars Zender; David R Tong; Angelo D'Alessandro; Scott W Lowe; Carol Prives
Journal:  Cell       Date:  2018-12-20       Impact factor: 41.582

6.  Exosomes secreted by placental stem cells selectively inhibit growth of aggressive prostate cancer cells.

Authors:  Taylor C Peak; Prakash P Praharaj; Gati K Panigrahi; Michael Doyle; Yixin Su; Isabel R Schlaepfer; Ravi Singh; Donald J Vander Griend; Julie Alickson; Ashok Hemal; Anthony Atala; Gagan Deep
Journal:  Biochem Biophys Res Commun       Date:  2018-04-09       Impact factor: 3.575

7.  Amniotic Fluid Exosome Proteomic Profile Exhibits Unique Pathways of Term and Preterm Labor.

Authors:  C Luke Dixon; Samantha Sheller-Miller; George R Saade; Stephen J Fortunato; Andrew Lai; Carlos Palma; Dominic Guanzon; Carlos Salomon; Ramkumar Menon
Journal:  Endocrinology       Date:  2018-05-01       Impact factor: 4.736

8.  LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis.

Authors:  Adam Ceroi; David Masson; Anne Roggy; Christophe Roumier; Cécile Chagué; Thierry Gauthier; Laure Philippe; Baptiste Lamarthée; Fanny Angelot-Delettre; Francis Bonnefoy; Sylvain Perruche; Sabeha Biichle; Claude Preudhomme; Elisabeth Macintyre; Laurent Lagrost; Francine Garnache-Ottou; Philippe Saas
Journal:  Blood       Date:  2016-10-04       Impact factor: 22.113

9.  Lin28 enhances de novo fatty acid synthesis to promote cancer progression via SREBP-1.

Authors:  Yang Zhang; Chenchen Li; Chuanzhen Hu; Qian Wu; Yongping Cai; Songge Xing; Hui Lu; Lin Wang; Linchong Sun; Tingting Li; Xiaoping He; Xiuying Zhong; Junfeng Wang; Ping Gao; Zachary J Smith; Weidong Jia; Huafeng Zhang
Journal:  EMBO Rep       Date:  2019-08-05       Impact factor: 8.807

Review 10.  The interplay between cell signalling and the mevalonate pathway in cancer.

Authors:  Peter J Mullen; Rosemary Yu; Joseph Longo; Michael C Archer; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2016-08-26       Impact factor: 60.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.